247 related articles for article (PubMed ID: 18058330)
21. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
22. Mdr1 limits CYP3A metabolism in vivo.
Lan LB; Dalton JT; Schuetz EG
Mol Pharmacol; 2000 Oct; 58(4):863-9. PubMed ID: 10999959
[TBL] [Abstract][Full Text] [Related]
23. CYP-mediated clozapine interactions: how predictable are they?
Chetty M; Murray M
Curr Drug Metab; 2007 May; 8(4):307-13. PubMed ID: 17504220
[TBL] [Abstract][Full Text] [Related]
24. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine.
Lutz JD; Kirby BJ; Wang L; Song Q; Ling J; Massetto B; Worth A; Kearney BP; Mathias A
Clin Pharmacol Ther; 2018 Dec; 104(6):1191-1198. PubMed ID: 29569712
[TBL] [Abstract][Full Text] [Related]
25. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
26. Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4.
Mouly S; Meune C; Bergmann JF
Intensive Care Med; 2009 Mar; 35(3):417-29. PubMed ID: 19132343
[TBL] [Abstract][Full Text] [Related]
27. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
28. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.
Kenworthy KE; Bloomer JC; Clarke SE; Houston JB
Br J Clin Pharmacol; 1999 Nov; 48(5):716-27. PubMed ID: 10594474
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel substrates for human cytochrome P450 2J2.
Lee CA; Neul D; Clouser-Roche A; Dalvie D; Wester MR; Jiang Y; Jones JP; Freiwald S; Zientek M; Totah RA
Drug Metab Dispos; 2010 Feb; 38(2):347-56. PubMed ID: 19923256
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens.
von Richter O; Burk O; Fromm MF; Thon KP; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2004 Mar; 75(3):172-83. PubMed ID: 15001968
[TBL] [Abstract][Full Text] [Related]
31. Functional interactions between P-glycoprotein and CYP3A in drug metabolism.
Christians U; Schmitz V; Haschke M
Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):641-54. PubMed ID: 16863430
[TBL] [Abstract][Full Text] [Related]
32. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.
Donato MT; Castell JV
Clin Pharmacokinet; 2003; 42(2):153-78. PubMed ID: 12537515
[TBL] [Abstract][Full Text] [Related]
33. CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies.
Engman HA; Lennernäs H; Taipalensuu J; Otter C; Leidvik B; Artursson P
J Pharm Sci; 2001 Nov; 90(11):1736-51. PubMed ID: 11745731
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
Katoh M; Nakajima M; Yamazaki H; Yokoi T
Eur J Pharm Sci; 2001 Feb; 12(4):505-13. PubMed ID: 11231118
[TBL] [Abstract][Full Text] [Related]
35. Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research.
Srinivas NR
Curr Clin Pharmacol; 2009 Sep; 4(3):220-8. PubMed ID: 19500074
[TBL] [Abstract][Full Text] [Related]
36. Psychotropic drug-drug interactions involving P-glycoprotein.
Akamine Y; Yasui-Furukori N; Ieiri I; Uno T
CNS Drugs; 2012 Nov; 26(11):959-73. PubMed ID: 23023659
[TBL] [Abstract][Full Text] [Related]
37. 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein.
Edwards DJ; Fitzsimmons ME; Schuetz EG; Yasuda K; Ducharme MP; Warbasse LH; Woster PM; Schuetz JD; Watkins P
Clin Pharmacol Ther; 1999 Mar; 65(3):237-44. PubMed ID: 10096255
[TBL] [Abstract][Full Text] [Related]
38. Induction of cytochrome P450 3A by Shexiang Baoxin Pill and its main components.
Jiang B; Cai F; Gao S; Meng L; Liang F; Dai X; Xu W; Chen W
Chem Biol Interact; 2012 Jan; 195(2):105-13. PubMed ID: 22178124
[TBL] [Abstract][Full Text] [Related]
39. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.
Runge D; Köhler C; Kostrubsky VE; Jäger D; Lehmann T; Runge DM; May U; Stolz DB; Strom SC; Fleig WE; Michalopoulos GK
Biochem Biophys Res Commun; 2000 Jun; 273(1):333-41. PubMed ID: 10873607
[TBL] [Abstract][Full Text] [Related]
40. Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism.
Shou M; Lu T; Krausz KW; Sai Y; Yang T; Korzekwa KR; Gonzalez FJ; Gelboin HV
Eur J Pharmacol; 2000 Apr; 394(2-3):199-209. PubMed ID: 10771285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
